Sema4, a Stamford, Conn.-based patient-centered health intelligence company, raised $121m in Series C financing.
Funds managed by BlackRock led the round at a post-money valuation of over $1 billion. Additional new investors include Deerfield Management Company and Moore Strategic Ventures. Each of the investors from first round of external funding participated in this second round, including Blackstone, Section 32, Oak HC/FT, Decheng, and Connecticut Innovations. As part of this deal, Andrew Elbardissi, MD Partner at Deerfield, has joined Sema4’s board of directors.
The company intends to use the funds to continue to expand operations and its business reach.
Spun out of the Mount Sinai Health System in June 2017 by Eric Schadt, PhD, Chief Executive Officer, Sema4 is a patient-centered health intelligence company building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellis™, its health intelligence platform, enables the company to generate a complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs.
Sema4 recently launched Sema4 Signal™, a family of products and services providing data-driven precision oncology solutions.